title: Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
abstract: Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.
authors.affiliation: Medical Oncology Unit, Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro and "Tommaso Campanella" Cancer Center, Campus Salvatore Venuta, Viale Europa, 88100 Catanzaro, Italy.
authors.forename: Iole
authors.initials: I
authors.lastname: Cucinotto
authors.forename: Lucia
authors.initials: L
authors.lastname: Fiorillo
authors.forename: Simona
authors.initials: S
authors.lastname: Gualtieri
authors.forename: Mariamena
authors.initials: M
authors.lastname: Arbitrio
authors.forename: Domenico
authors.initials: D
authors.lastname: Ciliberto
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Staropoli
authors.forename: Anna
authors.initials: A
authors.lastname: Grimaldi
authors.forename: Amalia
authors.initials: A
authors.lastname: Luce
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Tassone
authors.forename: Michele
authors.initials: M
authors.lastname: Caraglia
authors.forename: Pierosandro
authors.initials: P
authors.lastname: Tagliaferri